Drug Development Sector Scorecard – Thematic Research

The pharmaceutical industry is under increasing pressures with rising R&D costs, patent expiries, greater competition, and pricing challenges all eroding profit margins. Companies must invest in the right areas of drug development to maximize profitability and minimize risk.

Some of the most profitable or rapidly growing areas include immuno-oncology, regenerative medicine, precision and personalized medicine, biosimilars, genomics, and nanotechnology.

Companies can also forge strategic partnerships in R&D leading to risk diversification, new product development, shortened drug development timelines, and reduced costs. The industry is also investing in new technologies, such as artificial intelligence (AI) to improve drug development.

Our thematic scoring methodology is designed to identify tomorrow’s leaders rather than today’s incumbents, based on their competitive position in the 10 most important themes impacting the landscape.

Scope

GlobalData’s Drug Development Thematic Scorecard report provides a top-down, comprehensive future outlook for key players in the drug development sector over the next two to four years.

These themes are Immuno-oncology, Precision and Personalized Medicine, Regenerative Medicine, Rare Disease, Biosimilars, Genomics, Microbiome, Nanotechnology, Strategic Alliances, and Artificial Intelligence.

The scorecard includes 55 companies from across the industry, including biopharmaceutical companies, biosimilar and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs).

The methodology contains detailed information on what data sources were used to generate the thematic scores for each company.

Reasons to buy

Identify the key drug development themes for the next 2-4 years and learn how they will impact the market.

Understand which key themes should be addressed to drive share price.

Understand which companies are best positioned for success within critical themes and why.

Learn which companies have underinvested in key themes and are most vulnerable to disruption.

Help companies adapt their strategy to anticipate and benefit from these themes as they play out.

Help identify future winners and losers in drug development to inform partnership strategies.

Companies mentioned

Takeda Pharmaceutical Co Ltd

Merck & Co Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Pfizer Inc

Johnson & Johnson

Boehringer Ingelheim

Parexel International Corp

F. Hoffmann-La Roche Ltd

Novartis AG

GlaxoSmithKline Plc

Bayer AG

Eli Lilly and Co

IQVIA Holdings Inc

AbbVie Inc

Merck KGaA

Novo Nordisk AS

Catalent Inc

Gilead Sciences Inc

Thermo Fisher Scientific Inc

Astellas

Biogen Inc

Cipla Ltd

Lonza Group Ltd

Amgen Inc

Daiichi Sankyo Co Ltd

Vertex Pharmaceuticals Inc

WuXi AppTec Co Ltd

Charles River Laboratories International Inc

CSL Ltd

Reliance Life Sciences Pvt Ltd

Sanofi

Innovent Biologics Inc

Otsuka

Teva Pharmaceutical Industries Ltd

UCB

Dr. Reddy's Laboratories Ltd

Regeneron Pharmaceuticals Inc

Samsung Bioepis Co Ltd

Sun Pharmaceutical Industries Ltd

Alexion Pharmaceuticals Inc

Biocad

Cadila Pharmaceuticals Ltd

Celltrion Inc

Coherus BioSciences Inc

CSPC Pharmaceutical Group Ltd

Generium

Intas Pharmaceuticals Ltd

Lupin Ltd

Perrigo Co Plc

Pharmaceutical Product Development LLC

Seagen Inc

Shanghai Henlius Biotech Inc

Viatris Inc

Zydus Cadila

Table of Contents

Executive Summary

Introduction

Pharma Theme Map

Drug Development Scorecard

Company Screen

Thematic Screen

Valuation Screen

Our Thematic Research Methodology

How Our Pharma Scores Are Generated

Related Reports

About the Authors

About GlobalData

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports